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O B J E C T I V E S This study sought to determine the immediate and long-term effects of intraplaque
hemorrhage (IPH) on plaque progression in the carotid artery.
B A C KG ROUND Previous studies have associated IPH in the carotid artery with more rapid plaque
progression. However, the time course and long-term effect remain unknown. Carotid magnetic
resonance imaging is a noninvasive imaging technique that has been validated with histology for the
accurate in vivo detection of IPH and measurement of plaque burden.
METHOD S Asymptomatic subjects with 50% to 79% carotid stenosis underwent carotid magnetic
resonance imaging at baseline and then serially every 18 months for a total of 54 months. Subjects with
IPH present in at least 1 carotid artery at 54 months were selected. Subsequently, presence/absence of
IPH and wall volume were determined independently in all time points for both sides. A piece-wise
progression curve was ﬁt by using a linear mixed model to compare progression rates described as
annualized changes in wall volume between periods deﬁned by their relationship to IPH development.
R E S U L T S From 14 subjects who exhibited IPH at 54 months, 12 arteries were found to have
developed IPH during the study period. The progression rates were –20.5  13.1, 20.5  13.6, and
16.5  10.8 mm3/year before, during, and after IPH development, respectively. The progression rate
during IPH development tended to be higher than the period before (p  0.080) but comparable to the
period after (p 0.845). The progression rate in the combined period during/after IPH development was
18.3  6.5 mm3/year, which indicated signiﬁcant progression (p  0.008 compared with a slope of 0)
and was higher than the period before IPH development (p  0.018). No coincident ischemic events
were noted for new IPH.
CONC L U S I O N S The development of IPH posed an immediate and long-term promoting effect on
plaque progression. IPH seems to alter the biology and natural history of carotid atherosclerosis. Early
identiﬁcation of patients with IPH may prove invaluable in optimizing management to minimize future
sequelae. (J Am Coll Cardiol Img 2012;5:798–804) © 2012 by the American College of Cardiology
Foundation
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799T
here is increasing evidence that intraplaque
hemorrhage (IPH) is associated with high-
risk atherosclerotic carotid plaque. Prospective
studies have identified a compelling link be-
ween the presence of IPH at baseline and the
evelopment of future ischemic cerebrovascular events
n both previously asymptomatic and symptomatic
ndividuals (1–3). IPH has also been associated with a
ore rapid growth of the lipid-rich necrotic core and
ccelerated progression in plaque burden that seem to
nduce luminal narrowing regardless of initial stenotic
everity (4,5). However, the time course of these
eleterious effects remains undefined.
Understanding the immediate and long-term
mplications of IPH is particularly compelling. IPH
as been identified across a wide spectrum of stenosis
nd/or plaque burden (6–8). The acceleration of
laque growth on IPH development, if visualized in
he same artery, will support IPH as a direct
romoter for plaque progression. The duration of
ts effects, however, may primarily determine the
linical significance of IPH, especially in those
esions without luminal stenosis and with mini-
al plaque burden (6,7).
In this study, our goal was to determine the time
ourse of effects of IPH in the carotid artery. We
esigned a retrospective study consisting of partic-
pants enrolled in an ongoing natural history study
f carotid atherosclerotic disease imaged every 18
onths for 54 months with carotid magnetic reso-
ance imaging (MRI). Carotid MRI is a noninva-
ive imaging technique validated with histology for
he accurate in vivo detection of IPH and has
ecome an established approach for identifying
PH during cross-sectional and longitudinal studies
9–11).
M E T H O D S
Study sample. As part of a natural history study of
carotid atherosclerotic disease, participants were
recruited from the diagnostic vascular ultrasound
laboratories at the University of Washington Med-
ical Center, Veterans Affairs Puget Sound, and the
Virginia Mason Medical Center with the following
inclusion criteria: 1) 50% to 79% stenosis in at least
1 carotid artery; and 2) no cerebrovascular symp-
toms in the 6 months before enrollment. Study
procedures and consent forms were reviewed and
approved by the institutional review board at each
site. Written informed consent was obtained before
enrollment. wSubjects underwent carotid MRI at baseline and
then serially every 18 months for a total of 54
months. Routine medical care was directed by the
subjects’ primary care physicians during the entire
study duration. At the baseline MRI, a standardized
health questionnaire was completed and physical
examination was performed. Regular follow-ups
were conducted every 3 months by telephone inter-
view to record recent cerebrovascular events, occur-
rence of carotid endarterectomy (CEA), and cur-
rent medications. Subjects who provided a history
suggestive of an ischemic event during the tele-
phone interviews were evaluated and confirmed by
the study neurologist.
Imaging criteria for study inclusion were: 1) 54
months of imaging follow-up; and 2) presence of
IPH (see the Image Review section for criteria to
determine presence/absence of IPH) in at least 1
carotid artery at the most recent scan. Exclusion
criteria were: 1) history of CEA; and 2) image
quality 2 (see the Image Review section
for description of image quality).
MRI protocol. All images were acquired on
1.5-T scanner (Signa Horizon EchoS-
eed, GE Medical Systems, Milwaukee,
isconsin) by using phased-array surface
oils (Pathway MRI, Seattle, Washing-
on). A standardized carotid MRI proto-
ol was used to acquire multicontrast,
ross-sectional images (three-dimensional
ime-of-flight [TOF], T1-weighted
T1w], proton density–weighted [PDw],
nd T2-weighted [T2w]) centered at the
ifurcation of the carotid artery with 50%
o 79% stenosis, referred to as the index artery, as
reviously described (12,13). When both arteries
emonstrated 50% to 79% stenosis at baseline, 1
rtery was randomly chosen as the index artery for
entering of coverage during image acquisition.
uring subsequent acquisitions, the index artery
as always used for centering unless a CEA was
erformed on the index artery, in which case cen-
ering of coverage was switched to the contralateral
ide. Images were obtained with a field-of-view of
3 to 16 cm, matrix size of 256 256, and 2-mm slice
hickness. There was 1 mm of overlap between adja-
ent slices for TOF, and no interslice spacing for other
equences. Scan coverage was 40 mm for TOF, 20 to
4 mm for T1w, and 30 mm for PDw and T2w. Total
cquisition time was approximately 30 min.
Image review. All image interpretation was per-
ormed using a custom-designed image analysis soft-
A B B
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800(14) by researchers trained in carotid MRI and
blinded to clinical data. Image quality was rated per
scan on a 4-point scale (1  poor, 4  excellent),
onsistent with previous studies (15). Scans with
mage quality2 were excluded. Different weightings
ere registered during image review using the carotid
ifurcation as a reference. Scans without a carotid
ifurcation within the field-of-view were excluded.
The presence/absence of IPH in either carotid at
he final (54 months) time point (TP) was deter-
ined by a hyperintense signal on T1w and TOF
mages consistent with the presence of IPH as
reviously validated with histology at 1.5-T (9).
articipants with IPH at the 54-month TP in at
east 1 carotid artery were selected for additional
mage review that included both carotid arteries (i.e.,
PH arteries and their contralateral arteries) and also
ncluded all previous TPs (TP1  baseline scan,
P2  18 months, TP3  36 months, TP4  54
months). Multiple scans were matched, blinded to
time sequence, using the carotid bifurcation for each
participant. Only slices covered at all TPs were used
for analysis. Wall volume and presence of IPH were
determined independently at all TPs. PDw/T2w im-
ages were used to measure wall volume blinded to
presence/absence of IPH. TOF/T1w images were
used to determine presence/absence of IPH blinded to
the results from wall volume measurements.
Statistical analysis. Summary statistics of baseline
emographics are presented as mean  SDs for
ontinuous variables and count with percentage for
ategorical variables. Common coverage across
ultiple serial scans is presented as range with
edian for both TOF/T1w and PDw/T2w series.
erial data on IPH status were used to identify
rteries with new IPH. Wall volume was calculated
y summing wall areas on matched slices multiplied
y slice thickness, which was then normalized for
arying numbers of slices to yield a volume for 10
lices (wall volume/number of slices 10 slices) (4).
In arteries with new IPH during the study
eriod, the interscan interval when new IPH oc-
urred was defined as the IPH-new period. Periods
efore and after the IPH-new period were defined
s the IPH-absent and IPH-present periods, re-
pectively. To compare progression rates between
he 3 periods, and between the IPH-absent and the
ombined IPH-new/IPH-present period, a linear
ixed model approach was used (16). After recen-
ering the scan times around the occurrence of IPH
time  0 when IPH was first observed), a piece-
ise linear curve was fit between wall volume andime, with knots set at boundaries between periods. Aandom intercept was included in the model to ac-
ount for the dependence between multiple scans of
he same artery. Slopes  SEs of the piecewise linear
urve correspond to progression rates in wall volume
uring different periods, which were compared with 0
nd with each other by using Wald tests.
For the other arteries that did not show new IPH
uring the study period, the same linear mixed
odel approach was used to estimate their long-
erm average progression rates by fitting a single
ine over the entire study period (16).
All data analysis was performed by using R version
.11.0 (R Foundation for Statistical Computing, Vi-
nna, Austria). Statistical significance was defined as
 0.05.
R E S U L T S
Fourteen subjects with 54-month follow-up had
imaging evidence of IPH in at least 1 carotid artery
at their most recent scan. Baseline demographic
characteristics are shown in Table 1. In these 14
participants (n  28 carotid arteries), there were 17
carotid arteries with IPH present on MRI, 10
carotid arteries without IPH on MRI, and 1 artery
was excluded due to CEA during the 54-month
study period. The arteries at 54 months with (n 
17) and without (n 10) IPH were selected to have
their previous time point scans analyzed. Accord-
ingly, 108 scans (27 arteries  4 time points) were
available for review.
During the review of TOF/T1w series for IPH,
1 (3.7%) of the 27 arteries was excluded due to lack
of coverage of the carotid bifurcation at TP1 and
TP2. The remaining 26 arteries had serial data on
Table 1. Clinical Characteristics at Baseline (N  14)
Age, yrs 71.3 11.3
Male 13 (92.9)
Body mass index, kg/m2 28.0 3 .8
Current smoker 5 (35.7)
Hypertension* 12 (85.7)
Diabetes mellitus* 2 (14.3)
Hypercholesterolemia 12 (85.7)
History of CHD 6 (42.9)
Statin therapy 9 (64.3)
Antiplatelet agents 11 (78.6)
Aspirin 10 (71.4)
Clopidogrel 1 (7.1)
Cilostazol 1 (7.1)
Values are mean  SD or n (%). No subject was taking anticoagulant agents
at enrollment. *All subjects with hypertension and diabetes were receiving
corresponding medications at enrollment.
CHD  coronary heart disease.
w
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801IPH status at all 4 TPs. The common coverage of
TOF/T1w images across 4 scans ranged from 10 to
20 mm (median 16 mm). During the review of
PDw/T2w series for wall volume measurements, 16
(14.8%) scans were excluded due to poor image
quality. This left 26 arteries with wall volume
measurements at 2 to 4 TPs. The common coverage
of PDw/T2w images ranged from 10 to 28 mm
(median 24 mm).
Occurrence of IPH. Of the 26 arteries with serial data
on IPH, 4 (15.4%) had IPH present at all TPs
(IPH-present group; Fig. 1); 12 arteries (46.2%) did
not have IPH at the baseline scan and had IPH on
all subsequent scans after the occurrence of IPH
(IPH-new group; Fig. 2); 10 arteries (38.5%) did
not have IPH at any TPs (IPH-absent group).
Figure 1. A Representative Case of Arteries With IPH
at All Timepoints
White arrows indicate the presence of intraplaque hemorrhage
(IPH) at all time points (TPs) shown as bright areas on time-of-
ﬂight (TOF) images. L  lumen of internal carotid artery; T1w 0
T1-weighted.Resolution of IPH was not observed. Of the 12
arteries with new IPH, 10 (83.3%) were being
treated with statins when IPH occurred (Fig. 3).
Long-term effects of IPH. The annualized change in
all volume during the IPH-absent period was
20.5 13.1 mm3/year (p 0.129 compared with
a slope of 0 [Fig. 4]). Of the 7 arteries with an
IPH-absent period, 6 (85.7%) were being treated
with statins, and in 1 case, statin therapy was
initiated during this period (Fig. 3). During the
18-month IPH-new period, the annualized change
in wall volume was 20.5  13.6 mm3/year (p 
0.141 compared with a slope of 0 [Fig. 4]). Nine
(81.8%) of the 11 arteries with an IPH-new period
were on statin therapy during this period. The
annualized change in wall volume in the IPH-
present period was 16.5  10.8 mm3/year (p 
Figure 2. A Representative Case of Arteries With Incident IPH
White arrows indicate the presence of IPH at TP3/TP4, shown as
bright areas on TOF images. The IPH signal was absent at TP1/TP2.
Abbreviations as in Figure 1..138 compared with a slope of 0 [Fig. 4]). Six
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802(75.0%) of the 8 arteries with an IPH-present period
were being treated with statins, and in 1 case, statin
therapy was initiated during this period (Fig. 3). The
annualized change in wall volume during the IPH-
new period tended to be greater than that during the
IPH-absent period (p 0.080 for difference of slope)
ut comparable to that during the IPH-present period
p  0.845 for difference of slope). The annualized
hange in wall volume during the IPH-new/IPH-
resent period was 18.3  6.5 mm3/year (p  0.008
compared with a slope of 0), which is significantly
higher than that during the IPH-absent period (p 
0.018 for difference of slope).
The average progression rates over the entire
study period of IPH-present and IPH-absent arter-
ies were 34.2 9.0 mm3/year (p 0.004 compared
ith a slope of 0) and 5.3  7.2 mm3/year (p 
.466 compared with a slope of 0), respectively. All
PH-present arteries were being treated with statins
uring the study period. Of the IPH-absent arter-
es, 7 (77.8%) were being treated with statins during
he study period and in 1 case, statin therapy was
nitiated before its TP2 scan.
All 14 subjects with IPH at TP4 remained clinically
IPH
Appeared
During
Study
With
IPH at
Baseline
TP1 TP2 TP3 TP4
Ap
D
S
Figure 3. Serial Data on Presence/Absence of IPH and Medicatio
(Left) Four arteries showed IPH at all timepoints. Twelve arteries did
after the occurrence of IPH. (Right) Arteries are aligned according t
(IPH-absent, IPH-new, and IPH-present). Arteries that were being tre
relevant medications during study are marked under correspondingsymptomatic during the entire study period.D I S C U S S I O N
In this study using serial images of the in vivo carotid
artery over a 54-month period, the development of
IPH was found to be associated with an immediate
and long-term acceleration of plaque progression
compared with the period before. These observations
expand our understanding of the potentially central
role that IPH contributes to carotid atherosclerotic
disease in 2 important ways. First, acceleration of
plaque growth was seen coincidently with new IPH,
suggesting IPH is a direct promoter rather than a
bystander in plaque progression. Second, the acceler-
ating effects of IPH did not resolve after an extended
period of observation. These findings substantiate
previous animal studies (17) and human studies of a
shorter duration (4,5), which conjectured that the
presence of IPH may fundamentally alter the biology
of atherosclerotic disease. Therefore, the early identi-
fication of patients with IPH regardless of stenotic
severity or plaque burden may prove invaluable in
optimizing management to minimize future sequelae.
Although previous studies have identified an
association between IPH and stroke (1–3,18), the
Intervals with no IPH at both ends
Intervals with IPH only at the latter end
Intervals with IPH at both ends
Aspirin added Aspirin dropped Warfarin added
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hen IPH ﬁrst appeared. Three consecutive periods are deﬁned
with statins before enrollment are marked with S. Changes in
ervals. Abbreviations as in Figure 1.s
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tud
ns
no
o w
atedresults have largely been presented in the form of
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803increased event risk. In the current study, no coinci-
dent clinical symptoms were noted for new IPH. The
observation is supported by histopathologic studies
that have identified neovasculature originating from
the adventitia as a potential source of IPH (19,20),
which enables the development of IPH without dis-
ruption of the plaque surface. Collectively, it is implied
that the identification of IPH may stratify patients
with an advanced rate of plaque growth, but additional
features such as surface disruption may need to be
identified to better delineate patients at greatest risk
for stroke (21,22). Nevertheless, due to the small
sample size in this study, whether the occurrence of
new IPH is directly linked with cerebrovascular events
should be investigated further.
Statin therapy improves prognosis of cardiovas-
cular disease and has been shown to decrease plaque
burden in multiple imaging studies (23–25). We
found that 12 arteries developed new IPH during
the study period despite the fact that 10 (83.3%) of
them were being treated with statin therapy when
IPH occurred. The 4 arteries with IPH present
throughout the 54-month study period were pro-
gressing despite statin therapy, as did the 12 arteries
with new IPH after IPH developed. These findings
suggest that statin therapy alone may be insufficient
to prevent arteries from developing IPH and that
the effects of IPH may outweigh statin therapy in
determining plaque progression. Further studies are
needed to verify these observations in clinical trials.
Methemoglobin from hemoglobin breakdown after
erythrocyte extravasation has been proposed to ac-
count for the high signal intensity of IPH. How-
ever, the magnetic resonance signal of IPH is
distinctively durable compared with hemorrhage in
other pathological settings (26,27). Using a T1w
sequence for IPH detection, Yamada et al. (18)
reported that only 1 of 30 high signal intensity
carotid arteries changed to low signal intensity
during a median interval of 279 days (range 10 to
1,037 days). Two other studies using combined
TOF and T1w sequences for IPH detection did not
report any disappearance of IPH over an 18-month
period (4,5). Although the current study was not
designed to study the resolution of IPH, we found
that the hyperintense signal of IPH could last for as
long as 54 months. One possible explanation for
this phenomenon is that erythrocytes may continue
to extravasate from leaky vessels once IPH occurs
(4,20). Alternatively, the intraplaque environment
may be unique and yield an atypical degradation of
hemoglobin. Regardless, hemorrhage as detected by
MRI clearly persists in carotid atherosclerotic dis-ease, and further studies targeted at understanding
this unique occurrence may benefit the understand-
ing of the atherosclerotic disease process.
Study limitations. This study was limited by its small
sample size, which was primarily because the design
required that study participants not only have 4
serial scans using the same carotid imaging protocol
but also exhibit IPH on the last scan. However, this
is the first study, to the best of our knowledge, to
serially monitor at regular intervals the natural
history of atherosclerosis over an extended period.
In so doing, we found that the common coverage of
4 serial scans was generally smaller compared with
each individual scan alone but was comparable to
previous longitudinal studies that used only 2 TP
scans (5,28). In addition, the available coverage was
sufficient to cover lesions at the carotid bifurcation,
as is consistent with previous reports (8). This study
thus provides compelling evidence that monitoring
plaque progression by using serial imaging with a
validated MRI protocol is a promising approach for
long-term, large-scale studies of in vivo human
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804C O N C L U S I O N S
MRI monitoring of carotid arteries over a 54-
month period demonstrated the development of
IPH and the concurrent acceleration of plaque
growth despite a high prevalence of statin therapyidentifying lipid-rich necrotic cores and
intraplaque hemorrhage in advanced
1
1
1
1
1
1
1
1
1
1
intraplaque microvas
Coll Cardiol 2009;53alter the biology and natural history of carotid
atherosclerosis.
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